Ser520
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser520  -  MEKK2 (human)

Site Information
LsGtGMKsVtGtPYW   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1869000

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 ) , mutation of modification site ( 3 ) , phospho-antibody ( 3 ) , western blotting ( 3 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
anisomycin ( 3 ) , CpG-1668 ( 3 ) , EGF ( 3 ) , IL-1b ( 3 ) , LPS ( 3 ) , LTA ( 3 ) , nocodazole ( 3 ) , peptidoglycan ( 3 ) , sorbitol ( 3 ) , TNF ( 3 ) , UV ( 3 )

Downstream Regulation
Effects of modification on MEKK2:
enzymatic activity, induced ( 3 ) , phosphorylation ( 3 )
Effects of modification on biological processes:
transcription, altered ( 3 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

3

Zhang D, et al. (2006) Identification of MEKK2/3 serine phosphorylation site targeted by the Toll-like receptor and stress pathways. EMBO J 25, 97-107
16362041   Curated Info